Phase III trial of non-pegylated liposomal doxorubicin (M) in combination with trastuzumab (T) and paclitaxel (P) in HER2+ metastatic breast cancer (MBC).
Lorena De La Pena
No relevant relationships to disclose
Javier Cortes
Consultant or Advisory Role - Celgene; Novartis; Roche
Honoraria - Celgene; Eisai; Novartis; Roche
Alexey Manikhas
No relevant relationships to disclose
Laslo Roman
No relevant relationships to disclose
Vladimir Semiglazov
No relevant relationships to disclose
Mikhail Yu Biakhov
No relevant relationships to disclose
Lokanatha Dasappa
No relevant relationships to disclose
Antonio Llombart
Consultant or Advisory Role - GlaxoSmithKline; Roche
Honoraria - Roche; Teva
Marcel Rozencweig
Employment or Leadership Position - Sopherion Therapeutics
Stock Ownership - Sopherion Therapeutics
Salvatore Forenza
Employment or Leadership Position - Sopherion Therapeutics
Stock Ownership - Sopherion Therapeutics
Ronald H. Goldfarb
Employment or Leadership Position - Sopherion Therapeutics
Stock Ownership - Sopherion Therapeutics
Jeri Matera
No relevant relationships to disclose
Nozar Azarnia
Consultant or Advisory Role - Sopherion Therapeutics
Clifford Hudis
Research Funding - Merck
Other Remuneration - Estee Lauder Company (I)
Jose Baselga
No relevant relationships to disclose